Twinbeech Capital LP Crispr Therapeutics Ag Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $7.5 Million - $9.99 Million	146,473 New	146,473 $7.91 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $1.61 Million - $2.75 Million	37,247 New	37,247 $2.26 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $285,362 - $563,682	-7,412 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $249,636 - $463,472	7,412 New	7,412 $314,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.